Insights Into Eli Lilly and Co's Performance Versus Peers In Pharmaceuticals Sector
Insights Into Eli Lilly and Co's Performance Versus Peers In Pharmaceuticals Sector
In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Eli Lilly and Co (NYSE:LLY) in relation to its major competitors in the Pharmaceuticals industry. Through a detailed examination of key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and illuminate company's performance in the industry.
在今天快節奏且高度競爭的商業世界中，進行徹底的公司分析對於投資者和行業觀察者來說至關重要。在本文中，我們將進行廣泛的行業比較，評估紐交所(MRK)在藥品行業的主要競爭對手。通過對關鍵的財務指標、市場地位和增長前景進行詳細的考察，我們的目標是提供有價值的見解，闡明該公司在行業中的表現。禮來公司（紐交所：LLY）默沙東生產多種藥品，治療多種領域的疾病，包括心代謝症、癌症和感染。在癌症領域，該公司的免疫腫瘤學平台正在成爲總銷售額的主要貢獻者。該公司還具有實質性的疫苗業務，包括預防兒童疾病以及人類乳頭瘤病毒（HPV）治療。此外，默沙東出售與動物健康相關的藥品。從地理角度來看，公司銷售額的近一半來自於美國境內。
Eli Lilly and Co Background
禮來公司背景
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
禮來是一家專注於神經科學、心臟代謝、癌症和免疫學的製藥公司。禮來的主要產品包括用於癌症的維津尼奧；馬天尼羅、澤普邦、賈達信、特魯利康、胰島素諾和人用胰島素用於糖尿病；以及用於免疫學的塔吉特和優泰樂。
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co | 133.88 | 63.88 | 22.86 | 19.02% | $3.12 | $7.09 | 25.98% |
| Novo Nordisk A/S | 50.55 | 45.32 | 18.48 | 24.73% | $36.91 | $55.43 | 22.45% |
| Johnson & Johnson | 21.66 | 5.01 | 4.28 | 4.69% | $5.68 | $14.87 | 2.34% |
| Merck & Co Inc | 144.24 | 8.15 | 5.38 | 12.22% | $6.96 | $12.23 | 8.89% |
| AstraZeneca PLC | 38.61 | 6.47 | 5.13 | 5.69% | $4.47 | $10.46 | 16.55% |
| Novartis AG | 24.22 | 5.48 | 4.63 | 6.23% | $4.66 | $9.02 | 9.71% |
| Zoetis Inc | 34 | 15.92 | 9.31 | 11.91% | $0.93 | $1.55 | 9.5% |
| GSK PLC | 14 | 4.49 | 2.04 | 7.69% | $2.07 | $5.39 | 5.93% |
| Takeda Pharmaceutical Co Ltd | 45.23 | 0.89 | 1.53 | -0.04% | $86.09 | $668.37 | 9.91% |
| Dr Reddy's Laboratories Ltd | 18.83 | 3.73 | 3.76 | 4.77% | $20.32 | $41.48 | 12.49% |
| Jazz Pharmaceuticals PLC | 22.17 | 1.83 | 1.93 | -0.39% | $0.23 | $0.81 | 1.03% |
| Prestige Consumer Healthcare Inc | 16.70 | 2.10 | 3.10 | 3.04% | $0.09 | $0.15 | -3.11% |
| Corcept Therapeutics Inc | 30.53 | 6.09 | 6.76 | 5.22% | $0.03 | $0.14 | 38.95% |
| Average | 38.4 | 8.79 | 5.53 | 7.15% | $14.04 | $68.33 | 11.22% |
| 公司 | 市銷率P/S | 淨資產收益率ROE | 息稅前收入EBITDA (以十億計) | 毛利潤 (以十億計) | 營收增長 | CrowdStrike Holdings Inc (847.84) | 營業收入增長 |
|---|---|---|---|---|---|---|---|
| 禮來公司 | 133.88 | 63.88 | 22.86 | 19.02% | $3.12 | $7.09 | 25.98% |
| 諾和諾德 | 50.55 | 45.32 | 18.48 | 24.73% | $36.91 | $55.43 | 22.45% |
| 強生公司 | 21.66 | 5.01 | 4.28 | 4.69% | $5.68 | $14.87 | 2.34% |
| 默沙東(MRK)公司名稱 | 144.24 | 8.15 | 5.38 | 12.22% | $6.96 | $12.23 | 8.89% |
| 阿斯利康有限公司 | 38.61 | 6.47 | 5.13 | 5.69% | $4.47 | $10.46 | 16.55% |
| 諾華製藥 | 24.22 | 5.48 | 4.63 | 6.23% | $4.66 | $9.02 | 9.71% |
| Zoetis公司 | 34 | 15.92 | 9.31 | 11.91% | $0.93 | $1.55 | 9.5% |
| 葛蘭素史克製藥 | 14 | 4.49 | 2.04 | 7.69% | $2.07 | $5.39 | 5.93% |
| 武田製藥股份有限公司 | 45.23 | 0.89 | 1.53 | -0.04% | $86.09 | $668.37 | 9.91% |
| 如瑞迪博士（Dr Reddy's Laboratories Ltd） | 18.83 | 3.73 | 3.76 | 4.77% | $20.32 | $41.48 | 12.49% |
| 雅培製藥有限公司 | 22.17 | 1.83 | 1.93 | -0.39% | $0.23 | $0.81 | 1.03% |
| 普雷斯蒂奇消費保健公司 | 16.70 | 2.10 | 3.10 | 3.04% | $0.09 | 0.15美元 | -3.11% |
| 科匯生物 | 30.53 | 6.09 | 6.76 | 5.22% | 0.03美元 | 0.14美元 | 38.95% |
| 平均值 | 38.4 | 8.79 | 5.53 | 7.15% | $14.04 | $68.33 | 11.22% |
By closely examining Eli Lilly and Co, we can identify the following trends:
通過仔細研究禮來，我們可以確定以下趨勢：
The current Price to Earnings ratio of 133.88 is 3.49x higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
The elevated Price to Book ratio of 63.88 relative to the industry average by 7.27x suggests company might be overvalued based on its book value.
With a relatively high Price to Sales ratio of 22.86, which is 4.13x the industry average, the stock might be considered overvalued based on sales performance.
The Return on Equity (ROE) of 19.02% is 11.87% above the industry average, highlighting efficient use of equity to generate profits.
With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $3.12 Billion, which is 0.22x below the industry average, the company may face lower profitability or financial challenges.
With lower gross profit of $7.09 Billion, which indicates 0.1x below the industry average, the company may experience lower revenue after accounting for production costs.
With a revenue growth of 25.98%, which surpasses the industry average of 11.22%, the company is demonstrating robust sales expansion and gaining market share.
當前市盈率爲133.88。3.49x高於行業平均水平，表明該股票在市場情緒下被定價爲溢價水平。
市淨率爲40.11，相對於行業板塊水平高出5.78x，表明公司可能被高估，基於其賬面價值。63.88相對於行業板塊水平高出5.78x7.27x表明公司可能被高估，基於其賬面價值。
由於市銷率達到6.88x，高於行業平均水平，因此從銷售業績的角度來看，該股票可能被認爲被高估了。22.86，該值是4.13x由於盈利之前的利息、稅、折舊和攤銷(EBITDA)低於行業平均水平的0.01x，該公司可能面臨較低的盈利能力或財務挑戰。
該公司的roe19.02%。11.87%高於行業平均水平，突顯出資產、權益的高效利用帶來的盈利。
由於其更低的息稅折舊及攤銷前利潤（EBITDA）爲$3.12十億美元，該值是0.22倍這表示公司具有更低的毛利潤水平，低於行業平均水平。
由於較低的毛利潤$7.09十億美元，表明0.1倍低於行業平均水平，該公司可能在考慮生產成本後，經歷較低的營業收入。
營業收入增長爲25.98%，超過了行業平均水平的11.22%，說明公司展示了強勁的銷售擴張並獲得了市場份額。
Debt To Equity Ratio
債務權益比率
The debt-to-equity (D/E) ratio is a financial metric that helps determine the level of financial risk associated with a company's capital structure.
當比較Fiserv和其前四家同行公司的負債與股本比率時，會得出以下對比情況：
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
在行業比較中考慮債務權益比率可以簡明地評估公司的財務狀況和風險特徵，有助於投資者做出明智的決策。
When evaluating Eli Lilly and Co alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
將禮來與其前四大同行按負債權益比進行比較後，我們可以獲得以下見解：
Eli Lilly and Co has a higher debt-to-equity ratio of 2.05 compared to its top 4 peers.
This indicates a higher level of financial risk as the company relies more heavily on borrowed funds. Investors may perceive this as a potential concern.
禮來的負債權益比較高，爲2.05，高於其前四大同行公司。
這表明公司更加依賴借款資金，具有更高的財務風險。投資者可能會認爲這是一個潛在的問題。
Key Takeaways
要點
For Eli Lilly and Co in the Pharmaceuticals industry, the PE, PB, and PS ratios are all high compared to its peers, indicating potentially overvalued stock. On the other hand, the high ROE and revenue growth suggest strong profitability and future prospects. However, the low EBITDA and gross profit may raise concerns about operational efficiency and sustainability.
對於藥品行業的禮來而言，PE、PB和PS比率都比同行業高，可能表明其股票被高估。另一方面，高ROE和收入增長表明其盈利能力和未來前景強勁。然而，低EBITDA和毛利率可能引起人們對其經營效率和可持續性的擔憂。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動化內容引擎生成並由編輯審查。
譯文內容由第三人軟體翻譯。